U.S. markets close in 40 minutes
  • S&P 500

    3,927.25
    -161.60 (-3.95%)
     
  • Dow 30

    31,507.22
    -1,147.37 (-3.51%)
     
  • Nasdaq

    11,429.02
    -555.50 (-4.64%)
     
  • Russell 2000

    1,769.64
    -70.66 (-3.84%)
     
  • Crude Oil

    109.12
    -3.28 (-2.92%)
     
  • Gold

    1,820.00
    +1.10 (+0.06%)
     
  • Silver

    21.49
    -0.26 (-1.20%)
     
  • EUR/USD

    1.0478
    -0.0077 (-0.73%)
     
  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     
  • GBP/USD

    1.2347
    -0.0146 (-1.17%)
     
  • USD/JPY

    128.1500
    -1.2080 (-0.93%)
     
  • BTC-USD

    29,307.04
    -800.84 (-2.66%)
     
  • CMC Crypto 200

    655.36
    -15.31 (-2.28%)
     
  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     
  • Nikkei 225

    26,911.20
    +251.45 (+0.94%)
     

Global Lung Cancer Screening Market (2022 to 2027) - Featuring Ilumina, Abbott Laboratories and Thermo Fisher Scientific Among Others - ResearchAndMarkets.com

·3 min read

DUBLIN, January 20, 2022--(BUSINESS WIRE)--The "Lung Cancer Screening Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

According to the report estimates, Lung Cancer Screening Market is projected to reach US$ 16.7 Billion by 2027, from US$ 15.4 Billion in 2021.

Companies Mentioned

  • llumina, Inc..

  • Abbott Laboratories

  • Thermo Fisher Scientific, Inc

  • QIAGEN N.V.

  • Roche Holding AG

In recent years, lung cancer screening has enabled the detection of lung cancer before symptoms begin. Besides, the main aim of lung cancer screening is to detect lung cancer at its earliest and most treatable stage. Collectively, screening tests involve lab tests that monitor blood and other fluids, genetic tests that study for inherited genetic markers associated with illness, and imaging exams that produce pictures of the inside of the body. In addition, in lung cancer screening, individuals who have a high risk of developing lung cancer but no signs or symptoms of the disease undergo low-dose computed tomography (LDCT) scanning of the chest.

Globally, these screening is typically available to the general population. However, an individual's needs for a specific screening test are based on age, gender, and family history. Consequently, the lung cancer screening industry is thriving owing to the surge in the incidence of lung cancer due to the rising smoking population, technological progressions in screening, and expanding government support for the early detection of incidents. Moreover, strategic collaborations and renewed recommendations and guidelines on screening are also likely to surge the market growth in the coming years.

The evolution of the pandemic initially influenced the screening programs globally, particularly in the developed countries, owing to travel constraints and lockdowns imposed by governments. This commenced a decline in the number of people screened for this type of cancer. However, the resumption of services during the latter stages of Q2 and H2 2020 led to an expansion in the number of patients screened. This boost compensated for the decline in patients during H1 2020.

Nonetheless, the market is projected to display actual growth post-COVID-19 due to the escalation in demand for imaging solutions as non-essential operations and consultations were forced to be rescheduled when the general mortality ratio settled down. Further, these increase the need for screening and analytical equipment such as MRI, X-ray machinery, and automated tomography systems. The Global Lung Cancer Screening Industry will grow with a nominal CAGR of 1.4% during 2021-2027.

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Global Lung Cancer Screening Market and Volume Analysis

5.1 Market

5.2 Volume

6. Global Lung Cancer Screening Share Analysis

6.1 By Cancer Type

6.2 By End User

6.3 By Regions

7. Cancer Type - Global Lung Cancer Screening Market

7.1 Non-Small-cell Lung Cancer (NSCLC)

7.2 Small-cell Lung Cancer

8. End User - Global Lung Cancer Screening Market

8.1 Hospitals & Clinics

8.2 Diagnostic Centers

8.3 Research Institute

8.4 Others

9. Country - Lung Cancer Screening Statistics

10. Porters Five Forces

11. Company Analysis

For more information about this report visit https://www.researchandmarkets.com/r/dtzbqg

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005589/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900